Dupixent drives sales advancement in Sanofi's first quarter

Sanofi generated almost EUR 10bn in total sales during the year’s first three months. The French pharmaceutical firm gives several reasons why, one of which is a 45.7 percent growth of blockbuster drug Dupixent.

Photo: Charles Platiau/Reuters/Ritzau Scanpix

Thursday, French pharmaceutical firm Sanofi has publicized its financial figures for the first quarter of the year, reporting that total sales in the first three months came to EUR 9.7bn.

At constant exchange rates (CER), that makes a 8.6-percent positive difference from the same quarter last year.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs